Pfizer and Bio NTech on Friday submitted to the US Food and Drug Administration for emergency use authorization for their coronavirus vaccine candidate . 
This is the first coronavirus vaccine to seek regulatory clearance in the United States . 
The vaccine , known as BNT162b2 , could potentially be available for use in high risk populations in the United States by the middle to end of December , Pfizer and Bio NTech said in a statement earlier Friday . 
The vaccine requires two doses a few weeks apart , and protection is achieved 28 days after the first shot . 
The submission to the FDA is based on results from the Phase 3 clinical trial of Pfizer 's vaccine , which began in the United States on July 27 and enrolled more than 43,000 volunteers . 
The final analysis from the trial found the coronavirus vaccine was 95 % effective in preventing infections , even in older adults , and caused no serious safety concerns , Pfizer and Bio NTech said this week . 
The submission also includes safety data on about 100 children ages 12 to 15 . 
Read the full story : 
